Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 16Terminated 7Unknown 2Recruiting 2Withdrawn 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 9Genitourinary 1CNS 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 65Nivolumab 58Magnetic Resonance Spectroscopy 53enzalutamide 39Abiraterone Acetate 37Radiosurgery 36Gemcitabine 35Specimen Handling 32Radiotherapy 32Ipilimumab 32Androgen Antagonists 32Prednisone 31apalutamide 28Cisplatin 28Docetaxel 27Leuprolide 26atezolizumab 25Carboplatin 25durvalumab 23cabozantinib 23darolutamide 20acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 19olaparib 18Goserelin 17Radiation 16Gonadotropin-Releasing Hormone 16Biopsy 16gallium 68 PSMA-11 15Pluvicto 15avelumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Vinblastine × Genitourinary × Clear all
NCT05137262 2026-02-18

A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
12 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡